Ventripoint Issues Shares for Payment of Debenture Interest

Toronto, Ontario – TheNewswire - May 19 , 2026 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “ Corporation ”, TSXV:VPT) announces it has received approval from the TSX Venture Exchange (“ TSXV ”) and issued of 555,699 common shares (“ Shares ”) for the payment of an aggregate of $61,217 of interest owing on certain outstanding Convertible Debentures issued by the Corporation on September 20, 2024, March 21, 2025, September 2, 2025, and October 14, 2025. The Convertible Debentures bear interest at the rate of 10% per annum, payable every 6 months. The Shares will be issued at a deemed price of $0.11 and are subject to a hold period of 4 months and one day. The issuance of the Shares will not create a control person of the Corporation.   The Offering is a related party transaction within the meaning of TSXV Policy 5.9 and Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions (“MI-61-101”) as certain insiders of the Corporation received an aggregate of 15,778 Shares. The Corporation is relying on exemptions from the valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and (b) and 5.7(a) and (b) of MI 61-101, as the Corporation is not listed on a specified market and the fair market value of the participation in the transactions by insiders does not exceed 25% of the market capitalization of the Corporation, as determined in accordance with MI 61-101 and the fair market value of the transactions is not more than $2,500,000.